ACTRN12621000135819已完成1 期
Safety, tolerability and pharmacokinetics of high dose, subcutaneous infusions of benzathine penicillin G (Bicillin® L-A) in healthy adults
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •(a)Male and females aged 18 - 65 years at the time of screening.
- •(b)BMI between 20kg/m2 and 34.9kg/m2.
- •(c)No history of chronic renal impairment or significant liver dysfunction.
- •(d)No prior documented allergy to penicillin, cephalosporin antibiotics.
- •(e)Participants who are considered likely to adhere to the trial guidelines for the duration of the trial.
- •(f)Sign and dated informed consent in accordance with Good Clinical Practice (GCP)/Declaration of Helsinki.
- •(g)Participants must be in good state of health in the opinion of the investigator as indicated by a comprehensive clinical assessment (medical history and physical exam) and laboratory investigations (haematology, clinical chemistry, and urinalysis).
排除标准
- •(a)Currently taking penicillins or use of any penicillin-based antibiotics from screening through to the final study visit. The use of probenecid, NSAIDs, or other medications which may significantly alter the Bicillin® L-A PK will also not be permitted within 14 days prior to study drug administration until completion of the final follow-up visit. Sporadic NSAID use (<5 occasions) in the 14 days prior to drug administration will be allowed, but the need for ongoing regular NSAIDS will render the person ineligible due to NSAIDS effects on proximal tubular penicillin excretion. Hormonal contraceptives for females and occasional paracetamol and ibuprofen use is permitted while on study.
- •(b)Known soy allergy.
- •(c)History of adverse drug reaction or hypersensitivity.
- •(d)History of seizure disorder
- •(e)Receipt of an investigational product within 3 months of Dosing.
- •(f)Planned participation in another clinical trial concurrently.
- •(g)Pregnant or breastfeeding females.
- •(h)Existing dermatological conditions that may affect skin integrity at the site of injection.
- •(i)Planned operation/absence from the study site during the duration of the study.
- •(j)History within the last 12 months of intramuscular, or subcutaneous injection of the abdominal wall, or history of surgery to the buttocks, abdomen or abdominal wall within the last 12 months.
- •(k)History of radiotherapy.
- •(l)Use of any prescription medication or over-the-counter medication, herbal products, vitamins or minerals, within 7 days prior to study drug administration until completion of the final follow-up visit, unless in the opinion of the Principal Investigator or delegate the medication will not compromise participant safety or interfere with study procedures or data validity.
- •(m)Participants who are smokers must abstain from using tobacco products during the confinement period.
- •(n)Laboratory tests that fail to meet the following thresholds: one repeat will be allowed at discretion of the investigator to confirm eligibility.
- •i.Haematology: complete blood count (Haemoglobin, total white cell count and platelet count) – parameters within gender-specific reference intervals from PathWest unless deemed not clinically significant by the investigator.
- •ii.Clinical chemistry within gender-specific reference intervals from PathWest unless deemed not clinically significant by the investigator: urea, glucose, creatinine, sodium, potassium, chloride and bicarbonate, lactate dehydrogenase, calcium, total protein, magnesium, phosphate, albumin, cholesterol, and uric acid. For renal function an eGFR >90ml/min/m2 will be considered normal using the CKD-EPI without albuminuria on dipstick].
- •iii.Liver function tests (only at screening): aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, total bilirubin, gamma-glutamyl transferase [<1.5 x ULN (ALT, GGT; PathWest gender-specific reference ranges) will be considered not clinically significant].
- •iv.Negative HIV, Hepatitis B and C serology.
- •v.Negative pregnancy test at screening and check-in (females).
研究者
相似试验
已完成
1 期
The pharmacokinetics and clinical tolerability of ascending single doses of an oral tablet formulation of BNC210 in healthy male volunteersAnxiety disordersTrauma-and stressor-related disordersMental Health - AnxietyMental Health - Other mental health disordersACTRN12619001180101Bionomics Limited5
已完成
1 期
The pharmacokinetics and clinical tolerability of ascending single doses of BNC210, an anxiolytic compound, in healthy volunteersACTRN12609000577213Bionomics Limited4
尚未招募
不适用
Clofazimine and moxifloxacin PK, safety, and AccepTAbiLitY for paediatric TB treatment (CATALYST)TuberculosisPACTR202012756409365Stellenbosch University36
尚未招募
2 期
IVERSAL2: Pharmacokinetics safety and acceptability of DRV/r for children living with HIVHIV/AIDSPACTR202405769820746Fondazione Penta ETS50
已完成
1 期
Study to find out if the drug Vessel Dilator” is absorbed from an infusion under the skin and is safe and tolerated and improves heart function in people diagnosed with stable congestive heart failure and a moderate degree of kidney function loss.ACTRN12612000576820Madeleine Pharmaceuticals Pty Ltd18